Get the Stockscreener App
2.57
10.45%
-0.30
Genenta Science Spa Adr stock is traded at $2.57, with a volume of 284.56K.
It is down -10.45% in the last 24 hours and down -19.18% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$2.87
Open:
$2.88
24h Volume:
284.56K
Relative Volume:
0.49
Market Cap:
$47.00M
Revenue:
-
Net Income/Loss:
$-9.64M
P/E Ratio:
-4.8711
EPS:
-0.5276
Net Cash Flow:
$-6.76M
1W Performance:
-58.55%
1M Performance:
-19.18%
6M Performance:
-33.93%
1Y Performance:
-49.61%
1-Day Range:
$2.54
$2.93
1-Week Range:
$2.33
$4.06
52-Week Range:
$2.33
$10.00
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
2.57 | 67.25M | 0 | -9.64M | -6.76M | -0.5276 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Genenta Science Appoints New Board Member and Confirms CEO - MSN
Genenta Science Secures $15 Million in Registered Direct Offering - The Globe and Mail
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com India
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - MSN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com
Genenta Science stock plunges after $15 million ADS offering - Investing.com
Genenta Science stock plunges after $15 million ADS offering By Investing.com - Investing.com South Africa
Genenta Science appoints Dr. Francesco Galimi to board and approves 2024 financials By Investing.com - Investing.com South Africa
Genenta Science appoints Dr. Francesco Galimi to board and approves 2024 financials - Investing.com India
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewswire Inc.
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com UK
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 1.01% - Investing.com India
US Stock Market today: Dow, Nasdaq, S&P 500 open higher as US inflation data fuels Fed rate cut bets — Details here - Mint
Genenta Science Reports Reduced Losses and Strengthened Balance Sheet for H1 2025 - TipRanks
Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update - MarketBeat
Can Genenta Science S.p.A. (Common Stock) (K5F) stock hold up in economic slowdownGap Down & Community Driven Trade Alerts - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Stock Price Down 1.9%Here's What Happened - MarketBeat
Analyzing Genenta Science S.p.A. Depositary Receipt with multi timeframe chartsWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genenta Science S.p.A. Announces Shareholders’ Meeting for Strategic Amendments - TipRanks
Genenta Science (NASDAQ:GNTA) Trading 7.4% HigherHere's Why - MarketBeat
Real time alert setup for Trinity Capital Inc. performanceJuly 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Using data filters to optimize entry into Genenta Science S.p.A. Depositary ReceiptJuly 2025 News Drivers & High Accuracy Investment Signals - Newser
Assembly Biosciences Inc. stock trend outlook and recovery pathGDP Growth & Safe Capital Growth Tips - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Genenta Science (NASDAQ:GNTA) Trading 7.4% Higher – Time to Buy? - Defense World
Will Genenta Science S.p.A. Depositary Receipt stock go up soonJuly 2025 News Drivers & Entry and Exit Point Strategies - Newser
How moving averages guide Genenta Science S.p.A. Depositary Receipt tradingTrade Signal Summary & Safe Capital Investment Plans - Newser
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
Applying sector rotation models to Altice USA Inc.Free Risk Managed Intraday Trade Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com
Genenta secures $21.9 million for cancer drug trial - Investing.com
Oncology Breakthroughs: How Cancer Research Is Advancing in 202527.02.25News - Ariva
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
What is the current Price Target and Forecast for Genenta Science (GNTA) - Zacks Investment Research
GNTA Forecast — Price Target — Prediction for 2026 - TradingView
10 Best Italian Stocks To Buy Now - Yahoo Finance
Trading Halts Explained - MarketBeat
Genenta Science S.p.A.: Shareholders Board Members Managers and Company Profile | US36870W1009 - MarketScreener
GNTA Stock Price and Chart — NASDAQ:GNTA - TradingView
Stock Market Alerts - MarketBeat
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):